References
  1. Werfel T, Allam JP, Biedermann T, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336‐349
  2. Muraro A, Lemanske RF Jr, Hellings PW, et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2016;137(5):1347‐1358
  3. Leonard A, Wang J, Yu L, et al. Atopic Dermatitis Endotypes Based on Allergen Sensitization, Reactivity to Staphylococcus aureus Antigens, and Underlying Systemic Inflammation. J Allergy Clin Immunol Pract. 2020;8(1):236‐247.
  4. Jiao Q, Qian Q, Liu C, et al. T helper 22 cells from Han Chinese patients with atopic dermatitis exhibit high expression of inducible T-cell costimulator. Br J Dermatol. 2020;182(3):648‐657
  5. Ogg G. Natural killer cells get under your skin. Sci Transl Med.2020;12(532):eaba9181
  6. Celebi Sözener Z, Cevhertas L, Nadeau K, Akdis M, Akdis CA. Environmental factors in epithelial barrier dysfunction. J Allergy Clin Immunol. 2020;145(6):1517‐1528
  7. Pavel AB, Zhou L, Diaz A, et al. The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature. J Am Acad Dermatol. 2020;82(3):690‐699
  8. Guttman-Yassky E, Diaz A, Pavel AB, et al. Use of Tape Strips to Detect Immune and Barrier Abnormalities in the Skin of Children With Early-Onset Atopic Dermatitis JAMA Dermatol. 2019;155(12):1358‐1370
  9. Eyerich K, Brown SJ, Perez White BE, et al. Human and computational models of atopic dermatitis: A review and perspectives by an expert panel of the International Eczema Council. J Allergy Clin Immunol. 2019;143(1):36‐45
  10. Lemonnier N, Melén E, Jiang Y, et al. A novel whole blood gene expression signature for asthma, dermatitis, and rhinitis multimorbidity in children and adolescents [published online ahead of print, 2020 Apr 11]. Allergy. 2020;10.1111/all.14314
  11. Akdis CA, Arkwright PD, Brüggen MC, et al. Type 2 immunity in the skin and lungs [published online ahead of print, 2020 Apr 22]. Allergy. 2020;10.1111/all.14318
  12. Agache I, Akdis CA. Endotypes of allergic diseases and asthma: An important step in building blocks for the future of precision medicine. Allergol Int. 2016;65(3):243‐252
  13. Eyerich S, Metz M, Bossios A, Eyerich K. New biological treatments for asthma and skin allergies. Allergy. 2020;75(3):546‐560
  14. Ong PY. Moving toward a more precise treatment of atopic dermatitis. Ann Allergy Asthma Immunol. 2018;120(1):3‐4.
  15. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928
  16. Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the quality of evidence–publication bias. J Clin Epidemiol. 2011;64(12):1277
  17. Lundh A, Lexchin J, Mintzes B, et al. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017;2:MR000033.
  18. Bero LA. Why the Cochrane risk of bias tool should include funding source as a standard item. Cochrane Database Syst Rev. 2013;(12):ED000075..
  19. Evers S, Goossens M, de Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care. 2005;21(2):240-5.
  20. Hutter F, Antonanzas F. Economic evaluations in the EURONHEED: a comparative analysis. Pharmacoeconomics. 2009;27(7):561-70.
  21. Nixon J, Rice S, Drummond M, et al. Guidelines for completing the EURONHEED transferability information checklists. Eur J Health Econ. 2009;10(2):157-65
  22. Rucker G, Cates CJ, Schwarzer G. Methods for including information from multi-arm trials in pairwise meta-analysis. Res Synth Methods. 2017;8(4):392-403.
  23. Rucker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I2 in assessing heterogeneity may mislead. BMC medical research methodology. 2008;8(1):79
  24. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-6.
  25. Guyatt GH, Oxman AD, Sultan S, et al; GRADE Working Group. GRADE guidelines. Rating up the quality of evidence. J Clin Epidemiol. 2011;64(12):1311-6
  26. Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10‐19.
  27. Schram ME, Spuls PI, Leeflang MM, et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012; 67: 99-106
  28. Hanifin JM, Thurston M, Omoto M, ey al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11-8.
  29. Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol 2004; 140: 1513-19.
  30. Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27-33.
  31. Simpson EL, de Bruin-Weller M, Eckert L, et al. Responder Threshold for Patient-Oriented Eczema Measure (POEM) and Children’s Dermatology Life Quality Index (CDLQI) in Adolescents with Atopic Dermatitis. Dermatol Ther (Heidelb). 2019;9(4):799‐805
  32. Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012; 92: 502-7.
  33. Reich A, Halupczok J, Ramus M, et al. New data on the validation of VAS and NRS in pruritus assessment: minimal clinically important difference and itch frequency measurement. Acta Derm Venereol 2011; 91: 636.
  34. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002;52(2):69‐77
  35. Santesso 2020: Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, GRADE Working Group, et.al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol. 2020; 119:126-135.
  36. Thaçi D, Simpson EL, Beck LA, et.al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016; 387(10013):40-52
  37. Simpson EL, Bieber T, Guttman-Yassky E, et.al. SOLO 1 and SOLO 2 Investigators. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335-2348
  38. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287-2303.
  39. de Bruin-Weller M, Thaçi D, Smith CH, et. al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol. 2018; 178(5):1083-1101
  40. Simpson EL, Paller AS, Siegfried EC, et al.. Efficacy and Safety of Dupilumab in Adolescents with Uncontrolled Moderate to Severe Atopic Dermatitis: a Phase 3 Randomized Clinical Trial. AMA Dermatol. 2019;156(1):44-56.
  41. Worm M, Simpson EL, Thaci D, Bissonnette R, Lacour JP, Beissert S, et al. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2019; 156(2):131-143.
  42. ICER. Institute for Clinical and Economic Review. Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value. Evidence Report; 2017. Available from: https://icer-review.org/material/atopic-dermatitis-evidence-report/. Accessed December 7, 2019.
  43. Kuznik A, Bégo-Le-Bagousse G, Eckert L, et al. Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults. Dermatol Ther (Heidelb). 2017; 7(4): 493-505.
  44. Zimmermann M, Rind D, Chapman R, et al. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis. J Drugs Dermatol. 2018; 17(7): 750-756
  45. CADTH 2020] CADTH. Canadian Agency for Drugs and Technologies in Health. Common drug review. Pharmacoeconomic review report. Dupilumab (DUPIXENT. Sanofi-Aventis Canada Inc.). Moderate-to-severe atopic dermatitis. 2018. Available from:https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0533_Dupixent_PE_Report.pdf. Accessed May 20, 2020
  46. NICE. Dupilumab for treating moderate to severe atopic dermatitis. Technology appraisal guidance. 2018. Available from: www.nice.org.uk/guidance/ta534. Accessed May 20, 2020.
  47. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796-7.
  48. Edwards HA, McMeniman EK. The cost of dupilumab treatment for severe atopic dermatitis is largely offset by broader health-care savings and improvement in quality of life. Australas J Dermatol. 2020;61(2):e273-e275
  49. Wang FP, Tang XJ, Wei CQ, et al. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. J Dermatol Sci. 2018;90(2):190-198.
  50. Snast I, Reiter O, Hodak E, et al. Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis. Am J Clin Dermatol. 2018;19(2):145-165.
  51. Drucker AM, Ellis AG, Bohdanowicz M, et.al. Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis. JAMA Dermatol. 2020;156(6):1-10.
  52. Wollenberg A, Beck LA, Blauvelt A, et al. Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitis. Br J Dermatol. 2020;182(6):e186-e209.
  53. Deleuran M, Thaçi D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377-388
  54. Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol . 2020;182(1):85-96
  55. Bosma AL, de Wijs LEM, Hof MH, et al. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry [published online ahead of print, 2020 May 30]. J Am Acad Dermatol. 2020;S0190-9622(20)31004-5.